Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; Webster, A; Smith, D; Lorigan, P; Nathan, P; Larkin, J

Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; Webster, A; Smith, D; Lorigan, P; Nathan, P; Larkin, J.

Afiliação

Yip K; Ipswich Hospital, Ipswich, UK. Electronic address: kent.yip@nhs.net.
Melcher A; Institute of Cancer Research, Sutton, London, UK; The Royal Marsden Hospital, Chelsea, London, UK.
Harrington K; Institute of Cancer Research, Sutton, London, UK; The Royal Marsden Hospital, Chelsea, London, UK.
Illidge T; University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Withington, Manchester, UK.
Nobes J; Norfolk and Norwich University Hospital, Norwich, UK.
Webster A; Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Northwood, UK.
Smith D; The Royal Marsden Hospital, Chelsea, London, UK.
Lorigan P; University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Withington, Manchester, UK.
Nathan P; Mount Vernon Cancer Centre, Northwood, UK.
Larkin J; The Royal Marsden Hospital, Chelsea, London, UK.

Clin Oncol (R Coll Radiol) ; 30(4): 201-203, 2018 04.

Article em En | MEDLINE | ID: mdl-29402599

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Oncol (R Coll Radiol) Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google